Connor Iapoce is the assistant managing editor for 

joining the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to the movies, and playing with his cat, Squish. You can reach him at 

 delayed the target action date for the New Drug Application (NDA) for the investigational medicine, elamipretide, for the treatment of 

Announced on April 30, 2025, Stealth BioTherapeutics indicated that labelling discussions were initiated with the regulatory agency; however, a revised action date has yet to be communicated for the application for the ultra-rare, life-threatening disease.

"We appreciate the diligent efforts of the FDA to progress its review of our NDA, including its confirmation of post-marketing requirements and its recent initiation of labeling discussions," said Reenie McCarthy, Chief Executive Officer of Stealth BioTherapeutics.

 "We hope to gain more information on the revised action date in the coming days to inform our ability to continue supporting expanded and emergency access to elamipretide while advancing towards a potential FDA approval."

An ultra-rare, genetic mitochondrial disease, Barth syndrome, affecting fewer than 150 individuals in the US and 300 individuals worldwide, occurs primarily in males. The disease has been linked to exercise intolerance, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. Associated with a reduced life expectancy, approximately 85% of early deaths occur by age five—there are no approved therapies for the treatment of Barth syndrome.

The initial NDA was submitted by Stealth to the FDA on January 29, 2024, and filed for standard review in March, with a target action date of January 29, 2025. On May 6, the regulatory agency granted Priority Review designation to the application for elamipretide.

By October 2024, the FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) met and determined that elamipretide is effective for the treatment of Barth Syndrome. However, on January 14, 2025, the FDA announced its request for new analyses in November and December 2024 necessitated a delay of the PDUFA date to April 29, 2025.

The FDA has awarded Elamipretide with Orphan Drug, Fast Track, Priority Review, and Rare Pediatric designations for the treatment of Barth syndrome. Elamipretide has also received Orphan Drug designation from the European Medicines Agency (EMA).

In the release, Stealth Biotherapeutics announced that 35 patients worldwide have received expanded or emergency access to elamipretide for the treatment of Barth syndrome, including critically ill infants and toddlers impacted by the disease.

Stealth Biotherapeutics announces delay in FDA action date for Barth Syndrome Application. Stealth BioTherapeutics Inc. April 29, 2025. Accessed April 30, 2025. 

https://stealthbt.com/stealth-biotherapeutics-announces-delay-in-fda-action-date-for-barth-syndrome-application/

Ferreira C, Pierre G, Thompson R, Vernon H. Barth Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; October 9, 2014.

Rossi K. FDA grants orphan drug designation to Elamipretide for bath syndrome. HCP Live. February 4, 2021. Accessed April 30, 2025. 

https://www.hcplive.com/view/fda-grants-orphan-drug-designation-to-elamipretide-for-the-treatment-of-bath-syndrome

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

FDA News

RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

The FDA has postponed the target action date for the New Drug Application of elamipretide, a treatment for Barth syndrome, an ultra-rare genetic mitochondrial disease. Stealth BioTherapeutics, the company behind elamipretide, is engaged in labeling discussions with the FDA but awaits a revised action date. Barth syndrome, primarily affecting males, leads to severe health issues and has no approved treatments. Elamipretide has received multiple designations, including Orphan Drug and Priority Review, and has been made available to 35 patients through expanded or emergency access.

FDA further postpones action date for elamipretide, a potential treatment for Barth syndrome, as discussions on labeling progress.

FDA Delays Decision on Elamipretide for Barth Syndrome

Stealth Biotherapeutics announces delay in FDA action date for Barth Syndrome Application. Stealth BioTherapeutics Inc. April 29, 2025. Accessed April 30, 2025. https://stealthbt.com/stealth-biotherapeutics-announces-delay-in-fda-action-date-for-barth-syndrome-application/.

Ferreira C, Pierre G, Thompson R, Vernon H. Barth Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; October 9, 2014.

Rossi K. FDA grants orphan drug designation to Elamipretide for bath syndrome. HCP Live. February 4, 2021. Accessed April 30, 2025. https://www.hcplive.com/view/fda-grants-orphan-drug-designation-to-elamipretide-for-the-treatment-of-bath-syndrome.